- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
HIPAA 6020 Put on Back Burner, for Now
Health care stakeholders struggling to comply with the HIPAA 5010 transaction sets need not worry about one thing-- the next-generation 6020 transactions are not coming to a theater near you any time soon.
The 6020 transactions are being developed and are undergoing a public comment period that closes on March 7, 2012. But Accredited Standards Committee X12, developer of the HIPAA transactions, will not soon recommend adoption of technical reports, called TR3s, which would be a major step toward adoption of 6020.
The committee recognizes that the industry is not ready to begin another implementation cycle at this time, says ASC X12 chair Cathy Sheppard. However, public comments on the 6020 technical reports still are important in shaping the next version of HIPAA transactions to meet business needs.
More information is available athttp://forums.x12.org.
Source: Health Data Management
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Gestational Diabetes Is a Key Population Health Opportunity
December 7th 2023Diagnosing and treating gestational diabetes can have long-term positive effects on the health of the mother and the baby, warranting a distinct focus on the condition, according to an Institute for Value-Based Medicine® event held in Cleveland, Ohio.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
